These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

725 related articles for article (PubMed ID: 27144850)

  • 1. Ozanimod Induction and Maintenance Treatment for Ulcerative Colitis.
    Sandborn WJ; Feagan BG; Wolf DC; D'Haens G; Vermeire S; Hanauer SB; Ghosh S; Smith H; Cravets M; Frohna PA; Aranda R; Gujrathi S; Olson A;
    N Engl J Med; 2016 May; 374(18):1754-62. PubMed ID: 27144850
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Ozanimod as Induction and Maintenance Therapy for Ulcerative Colitis.
    Sandborn WJ; Feagan BG; D'Haens G; Wolf DC; Jovanovic I; Hanauer SB; Ghosh S; Petersen A; Hua SY; Lee JH; Charles L; Chitkara D; Usiskin K; Colombel JF; Laine L; Danese S;
    N Engl J Med; 2021 Sep; 385(14):1280-1291. PubMed ID: 34587385
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Etrolizumab as induction and maintenance therapy for ulcerative colitis in patients previously treated with tumour necrosis factor inhibitors (HICKORY): a phase 3, randomised, controlled trial.
    Peyrin-Biroulet L; Hart A; Bossuyt P; Long M; Allez M; Juillerat P; Armuzzi A; Loftus EV; Ostad-Saffari E; Scalori A; Oh YS; Tole S; Chai A; Pulley J; Lacey S; Sandborn WJ;
    Lancet Gastroenterol Hepatol; 2022 Feb; 7(2):128-140. PubMed ID: 34798039
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Etrolizumab for maintenance therapy in patients with moderately to severely active ulcerative colitis (LAUREL): a randomised, placebo-controlled, double-blind, phase 3 study.
    Vermeire S; Lakatos PL; Ritter T; Hanauer S; Bressler B; Khanna R; Isaacs K; Shah S; Kadva A; Tyrrell H; Oh YS; Tole S; Chai A; Pulley J; Eden C; Zhang W; Feagan BG;
    Lancet Gastroenterol Hepatol; 2022 Jan; 7(1):28-37. PubMed ID: 34798037
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Long-Term Efficacy and Safety of Ozanimod in Moderately to Severely Active Ulcerative Colitis: Results From the Open-Label Extension of the Randomized, Phase 2 TOUCHSTONE Study.
    Sandborn WJ; Feagan BG; Hanauer S; Vermeire S; Ghosh S; Liu WJ; Petersen A; Charles L; Huang V; Usiskin K; Wolf DC; D'Haens G
    J Crohns Colitis; 2021 Jul; 15(7):1120-1129. PubMed ID: 33438008
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Efficacy and safety of adalimumab in paediatric patients with moderate-to-severe ulcerative colitis (ENVISION I): a randomised, controlled, phase 3 study.
    Croft NM; Faubion WA; Kugathasan S; Kierkus J; Ruemmele FM; Shimizu T; Mostafa NM; Venetucci M; Finney-Hayward T; Sanchez Gonzalez Y; Bereswill M; Lazar A; Turner D
    Lancet Gastroenterol Hepatol; 2021 Aug; 6(8):616-627. PubMed ID: 34153231
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Ozanimod in Patients With Moderate to Severe Ulcerative Colitis Naive to Advanced Therapies.
    Sands BE; D'Haens G; Panaccione R; Regueiro M; Ghosh S; Hudesman D; Ahmad HA; Mehra D; Wu H; Jain A; Petersen A; Osterman MT; Afzali A; Danese S
    Clin Gastroenterol Hepatol; 2024 Oct; 22(10):2084-2095.e4. PubMed ID: 38723981
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Ozanimod induction therapy for patients with moderate to severe Crohn's disease: a single-arm, phase 2, prospective observer-blinded endpoint study.
    Feagan BG; Sandborn WJ; Danese S; Wolf DC; Liu WJ; Hua SY; Minton N; Olson A; D'Haens G
    Lancet Gastroenterol Hepatol; 2020 Sep; 5(9):819-828. PubMed ID: 32553149
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Vedolizumab as induction and maintenance therapy for ulcerative colitis.
    Feagan BG; Rutgeerts P; Sands BE; Hanauer S; Colombel JF; Sandborn WJ; Van Assche G; Axler J; Kim HJ; Danese S; Fox I; Milch C; Sankoh S; Wyant T; Xu J; Parikh A;
    N Engl J Med; 2013 Aug; 369(8):699-710. PubMed ID: 23964932
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Safety and efficacy of ozanimod versus interferon beta-1a in relapsing multiple sclerosis (SUNBEAM): a multicentre, randomised, minimum 12-month, phase 3 trial.
    Comi G; Kappos L; Selmaj KW; Bar-Or A; Arnold DL; Steinman L; Hartung HP; Montalban X; Kubala Havrdová E; Cree BAC; Sheffield JK; Minton N; Raghupathi K; Ding N; Cohen JA;
    Lancet Neurol; 2019 Nov; 18(11):1009-1020. PubMed ID: 31492651
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cobitolimod for moderate-to-severe, left-sided ulcerative colitis (CONDUCT): a phase 2b randomised, double-blind, placebo-controlled, dose-ranging induction trial.
    Atreya R; Peyrin-Biroulet L; Klymenko A; Augustyn M; Bakulin I; Slankamenac D; Miheller P; Gasbarrini A; Hébuterne X; Arnesson K; Knittel T; Kowalski J; Neurath MF; Sandborn WJ; Reinisch W;
    Lancet Gastroenterol Hepatol; 2020 Dec; 5(12):1063-1075. PubMed ID: 33031757
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Etrolizumab versus adalimumab or placebo as induction therapy for moderately to severely active ulcerative colitis (HIBISCUS): two phase 3 randomised, controlled trials.
    Rubin DT; Dotan I; DuVall A; Bouhnik Y; Radford-Smith G; Higgins PDR; Mishkin DS; Arrisi P; Scalori A; Oh YS; Tole S; Chai A; Chamberlain-James K; Lacey S; McBride J; Panés J;
    Lancet Gastroenterol Hepatol; 2022 Jan; 7(1):17-27. PubMed ID: 34798036
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Safety and efficacy of the selective sphingosine 1-phosphate receptor modulator ozanimod in relapsing multiple sclerosis (RADIANCE): a randomised, placebo-controlled, phase 2 trial.
    Cohen JA; Arnold DL; Comi G; Bar-Or A; Gujrathi S; Hartung JP; Cravets M; Olson A; Frohna PA; Selmaj KW;
    Lancet Neurol; 2016 Apr; 15(4):373-81. PubMed ID: 26879276
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Filgotinib as induction and maintenance therapy for ulcerative colitis (SELECTION): a phase 2b/3 double-blind, randomised, placebo-controlled trial.
    Feagan BG; Danese S; Loftus EV; Vermeire S; Schreiber S; Ritter T; Fogel R; Mehta R; Nijhawan S; Kempiński R; Filip R; Hospodarskyy I; Seidler U; Seibold F; Beales ILP; Kim HJ; McNally J; Yun C; Zhao S; Liu X; Hsueh CH; Tasset C; Besuyen R; Watanabe M; Sandborn WJ; Rogler G; Hibi T; Peyrin-Biroulet L
    Lancet; 2021 Jun; 397(10292):2372-2384. PubMed ID: 34090625
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Ozanimod: A Review in Ulcerative Colitis.
    Paik J
    Drugs; 2022 Aug; 82(12):1303-1313. PubMed ID: 35994200
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Safety and efficacy of ozanimod versus interferon beta-1a in relapsing multiple sclerosis (RADIANCE): a multicentre, randomised, 24-month, phase 3 trial.
    Cohen JA; Comi G; Selmaj KW; Bar-Or A; Arnold DL; Steinman L; Hartung HP; Montalban X; Kubala Havrdová E; Cree BAC; Sheffield JK; Minton N; Raghupathi K; Huang V; Kappos L;
    Lancet Neurol; 2019 Nov; 18(11):1021-1033. PubMed ID: 31492652
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Tofacitinib, an oral Janus kinase inhibitor, in active ulcerative colitis.
    Sandborn WJ; Ghosh S; Panes J; Vranic I; Su C; Rousell S; Niezychowski W;
    N Engl J Med; 2012 Aug; 367(7):616-24. PubMed ID: 22894574
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Ustekinumab as Induction and Maintenance Therapy for Ulcerative Colitis.
    Sands BE; Sandborn WJ; Panaccione R; O'Brien CD; Zhang H; Johanns J; Adedokun OJ; Li K; Peyrin-Biroulet L; Van Assche G; Danese S; Targan S; Abreu MT; Hisamatsu T; Szapary P; Marano C;
    N Engl J Med; 2019 Sep; 381(13):1201-1214. PubMed ID: 31553833
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Anti-MAdCAM antibody (PF-00547659) for ulcerative colitis (TURANDOT): a phase 2, randomised, double-blind, placebo-controlled trial.
    Vermeire S; Sandborn WJ; Danese S; Hébuterne X; Salzberg BA; Klopocka M; Tarabar D; Vanasek T; Greguš M; Hellstern PA; Kim JS; Sparrow MP; Gorelick KJ; Hinz M; Ahmad A; Pradhan V; Hassan-Zahraee M; Clare R; Cataldi F; Reinisch W
    Lancet; 2017 Jul; 390(10090):135-144. PubMed ID: 28527704
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Lyophilised oral faecal microbiota transplantation for ulcerative colitis (LOTUS): a randomised, double-blind, placebo-controlled trial.
    Haifer C; Paramsothy S; Kaakoush NO; Saikal A; Ghaly S; Yang T; Luu LDW; Borody TJ; Leong RW
    Lancet Gastroenterol Hepatol; 2022 Feb; 7(2):141-151. PubMed ID: 34863330
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 37.